Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
Blood AdvSep 6, 2026
Joseph P McGuirk, Armin Ghobadi, Carlos R Bachier et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, single-arm, phase 1/2 trial assessed the safety and efficacy of CD19-directed CAR-T therapy CTX110 in 63 adults with relapsed/refractory B-cell non-Hodgkin lymphoma. The study found an objective response rate of 65% and a complete response rate of 39% among patients receiving higher dose levels. A second infusion improved response duration compared to a single infusion.
Key findings
- Objective response rate was 65% and complete response rate was 39% among patients receiving DL ≥3.
- Among 22 patients achieving complete response, 23% had ongoing complete response at data cutoff.
- The two-infusion regimen prolonged response duration compared to one infusion (hazard ratio, 0.65).
- Cytokine release syndrome occurred in 54% of treated patients.
Why it matters
The findings suggest that CTX110 can provide significant clinical responses in a heavily pretreated population with relapsed/refractory B-cell non-Hodgkin lymphoma, highlighting its potential as a treatment option in this challenging patient group.